These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 36532009)
1. Krebs von den lungen-6 as a clinical marker for hypersensitivity pneumonitis: A meta-analysis and bioinformatics analysis. He J; Zhang J; Ren X Front Immunol; 2022; 13():1041098. PubMed ID: 36532009 [TBL] [Abstract][Full Text] [Related]
2. YKL-40 and KL-6 Levels in Serum and Sputum of Patients Diagnosed With Hypersensitivity Pneumonitis. Sánchez-Díez S; Munoz X; Ojanguren I; Romero-Mesones C; Espejo D; Villar A; Gómez-Olles S; Cruz MJ J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2414-2423. PubMed ID: 35788062 [TBL] [Abstract][Full Text] [Related]
3. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Okamoto T; Fujii M; Furusawa H; Tsuchiya K; Miyazaki Y; Inase N Respir Med; 2015 Dec; 109(12):1576-81. PubMed ID: 26481343 [TBL] [Abstract][Full Text] [Related]
4. Krebs von den Lungen-6 (KL-6) is a pathophysiological biomarker of early-stage acute hypersensitivity pneumonitis among pigeon fanciers. Ji Y; Bourke SJ; Spears M; Wain LV; Boyd G; Lynch PP; Cunningham M; Boyd K; Donnelly I; Kohno N; McSharry C Clin Exp Allergy; 2020 Dec; 50(12):1391-1399. PubMed ID: 32966647 [TBL] [Abstract][Full Text] [Related]
5. Changes in serum KL-6 levels during short-term strict antigen avoidance are associated with the prognosis of patients with fibrotic hypersensitivity pneumonitis caused by avian antigens. Hanzawa S; Tateishi T; Ishizuka M; Inoue Y; Honda T; Kawahara T; Tomita M; Miyazaki Y Respir Investig; 2020 Nov; 58(6):457-464. PubMed ID: 32698996 [TBL] [Abstract][Full Text] [Related]
6. Krebs von den Lungen-6 (KL-6) as a diagnostic marker for pulmonary fibrosis: A systematic review and meta-analysis. Wang C; Wang Q; Liu T; Zhu J; Zhang B Clin Biochem; 2023 Apr; 114():30-38. PubMed ID: 36706799 [TBL] [Abstract][Full Text] [Related]
7. Role of Krebs von den Lungen-6 (KL-6) in Assessing Hypersensitivity Pneumonitis. Mostafa AI; Salem AE; Ahmed HAM; Bayoumi AI; Halim RMA; Samie RMA Tuberc Respir Dis (Seoul); 2021 Jul; 84(3):200-208. PubMed ID: 33840176 [TBL] [Abstract][Full Text] [Related]
8. Role of serum surfactant protein-D as a prognostic predictor in fibrotic hypersensitivity pneumonitis. Ejima M; Okamoto T; Suzuki T; Miyazaki Y Respir Investig; 2022 May; 60(3):369-378. PubMed ID: 34998715 [TBL] [Abstract][Full Text] [Related]
9. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review. d'Alessandro M; Bergantini L; Cameli P; Vietri L; Lanzarone N; Alonzi V; Pieroni M; M Refini R; Sestini P; Bonella F; Bargagli E Biomark Med; 2020 Jun; 14(8):665-674. PubMed ID: 32613855 [No Abstract] [Full Text] [Related]
10. Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis. Pramana Witarto A; Samarta Witarto B; Er Putra AJ; Pramudito SL; Rosyid AN Iran Biomed J; 2021 Nov; 25(6):381-9. PubMed ID: 34641641 [TBL] [Abstract][Full Text] [Related]
11. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases. Lederer C; Mayer K; Somogyi V; Kriegsmann K; Kriegsmann M; Buschulte K; Polke M; Findeisen P; Herth F; Kreuter M Respiration; 2023; 102(8):591-600. PubMed ID: 37586349 [TBL] [Abstract][Full Text] [Related]
12. KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Zhang T; Shen P; Duan C; Gao L Front Immunol; 2021; 12():745233. PubMed ID: 34956179 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis. Katayama K; Hirose M; Arai T; Hatsuda K; Tachibana K; Sugawara R; Sugimoto C; Kasai T; Akira M; Inoue Y Orphanet J Rare Dis; 2020 Sep; 15(1):272. PubMed ID: 32993757 [TBL] [Abstract][Full Text] [Related]
14. Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19: A Systematic Review, Meta-Analysis, and Trial Sequence Analysis. Shrestha AB; Pokharel P; Singh H; Shrestha S; Fioni Clin Med Insights Circ Respir Pulm Med; 2023; 17():11795484231152304. PubMed ID: 36710717 [TBL] [Abstract][Full Text] [Related]
15. Prediction Value of KREBS Von Den Lungen-6 (KL-6) Biomarker in COVID-19 Patients: A Systematic Review and Meta-Analysis. Matuszewski M; Szarpak L; Rafique Z; Peacock FW; Pruc M; Szwed P; Chirico F; Navolokina A; Ladny JR; Denegri A J Clin Med; 2022 Nov; 11(21):. PubMed ID: 36362828 [TBL] [Abstract][Full Text] [Related]
16. Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses. Naderi N; Rahimzadeh M Virology; 2022 Jan; 566():106-113. PubMed ID: 34896901 [TBL] [Abstract][Full Text] [Related]
17. Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases. Cho EJ; Park KJ; Ko DH; Koo HJ; Lee SM; Song JW; Lee W; Lee HK; Do KH; Chun S; Min WK Ann Lab Med; 2019 May; 39(3):245-251. PubMed ID: 30623616 [TBL] [Abstract][Full Text] [Related]
19. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease. Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895 [TBL] [Abstract][Full Text] [Related]
20. The effectiveness and pharmacoeconomic study of using different corticosteroids in the treatment of hypersensitivity pneumonitis. Elhennawy MG; Akl Y; Abbassi M; Sabry NA BMC Pulm Med; 2024 Feb; 24(1):87. PubMed ID: 38360614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]